Skip to main content

Biogen Contract manufacturing, royalty and other revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

Contract manufacturing, royalty and other revenue at Biogen came to $149.7M for the quarter to 30 Sep 2026, down 1.0% from a year earlier.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$176.8MJun 2023$304.2MSep 2023$181.8MMar 2024$109.0MJun 2024$231.6MSep 2024$130.2MDec 2024$293.3MMar 2025$244.6MJun 2025$151.2MSep 2025$246.9MMar 2026$242.4MJun 2026$149.7MSep 2026
Biogen Contract manufacturing, royalty and other revenue, every reported period
Period endingContract manufacturing, royalty and other revenueChange on a yearFiled
30 Sep 2026$149.7Mdown 1.0%28 Oct 2026
30 Jun 2026$242.4Mdown 0.9%29 Jul 2026
31 Mar 2026$246.9Mdown 15.8%29 Apr 2026
30 Sep 2025$151.2Mdown 34.7%30 Oct 2025
30 Jun 2025$244.6Mup 124.4%31 Jul 2025
31 Mar 2025$293.3Mup 61.3%1 May 2025
31 Dec 2024$130.2M—12 Feb 2025
30 Sep 2024$231.6Mdown 23.9%30 Oct 2024
30 Jun 2024$109.0Mdown 38.3%1 Aug 2024
31 Mar 2024$181.8M—24 Apr 2024
30 Sep 2023$304.2M—8 Nov 2023
30 Jun 2023$176.8M—25 Jul 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · QALSODY revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.